TNFRSF17 and plasma cell myeloma: BCMA is highly expressed in malignantplasma cells and represents a validated target in multiple myeloma.Belantamab mafodotin (Blenrep) is a novel ADC composed of an anti-BCMAantibody conjugated to MMAF via a noncleavable linker. In RPMI-8226 cells, which express moderate levelsof BCMA (normalized transcript per million (nTPM) = 171), Belantamab-LIPTACdemonstrated more efficient internalization than Belantamab (Figure a).